Old Web
English
Sign In
Acemap
>
authorDetail
>
Roberto Zajdenverg
Roberto Zajdenverg
GlaxoSmithKline
Medicine
Virology
Dolutegravir
Intensive care medicine
Randomized controlled trial
2
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
SEGURANÇA E EFICÁCIA DA TERAPIA ANTIRRETROVIRAL BASEADA EM DOLUTEGRAVIR, NA SEMANA 48, EM ADULTOS COINFECTADOS HIV/TB
2018
Brazilian Journal of Infectious Diseases
Kelly Elise Dooley
Richard Kaplan
Noluthando Mwelase
Beatriz Grinsztejn
Eduardo Ticona
Marcus V. G. Lacerda
Omar Sued
Elena Belonosova
Mounir Ait‐Khaled
Kostas Angelis
Dannae Brown
Rajendra P. Singh
Christine Talarico
Allan R. Tenorio
Michael R. Keegan
Michael Aboud
Roberto Zajdenverg
Show All
Source
Cite
Save
Citations (0)
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
2016
PLOS ONE
David A. Cooper
Damien V. Cordery
Roberto Zajdenverg
Kiat Ruxrungtham
Keikawus Arastéh
Frank Bergmann
José L. de Andrade Neto
Joseph Scherer
Ricardo L. Chaves
Patrick A. Robinson
Study Team
Show All
Source
Cite
Save
Citations (3)
1